Cargando…
Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
With the emergence of effective immunotherapeutics, which nevertheless harbor the potential for toxicity and are expensive to use, biomarkers are urgently needed for identification of cancer patients who respond to treatment. In this clinical-epidemiological study of 202 cancer patients treated with...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404794/ https://www.ncbi.nlm.nih.gov/pubmed/25949903 http://dx.doi.org/10.4161/2162402X.2014.989771 |